1887

Abstract

Bacteriophage therapy can be developed to target emerging diarrhoeal pathogens, but doing so in the absence of microbiome disruption, which occurs with antibiotic treatment, has not been established.

Identify a therapeutic bacteriophage that kills diarrhoeagenic enteroaggregative (EAEC) while leaving the human microbiome intact.

Phages from wastewater in Portland, OR, USA were screened for bacteriolytic activity by overlay assay. One isolated phage, , was classified by electron microscopy and genome sequencing. A mouse model of infection determined whether the phage was therapeutic against EAEC. 16S metagenomic analysis of anaerobic cultures determined whether a normal human microbiome was altered by treatment.

virus , a member of the strictly lytic family , killed a case-associated EAEC isolate from a child in rural Tennessee in a dose-dependent manner, and killed EAEC isolates from Columbian children. A single dose of (multiplicity of infection: 100) 1 day post-infection reduced EAEC recovered from mouse faeces. also killed EAEC when cultured anaerobically in the presence of human faecal bacteria. While the addition of EAEC reduced the β-diversity of the human microbiota, that of the cultures with either faeces alone, faeces with EAEC and , or with just phage was not different statistically.

killed EAEC isolate EN1E-0007 and , while not altering the diversity of normal human microbiota in anaerobic culture, and thus could be part of an effective therapy for children in developing countries and those suffering from EAEC-mediated traveller’s diarrhoea without causing dysbiosis.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001162
2020-02-03
2020-02-28
Loading full text...

Full text loading...

/deliver/fulltext/jmm/69/2/309.html?itemId=/content/journal/jmm/10.1099/jmm.0.001162&mimeType=html&fmt=ahah

References

  1. Kaur P, Chakraborti A, Asea A. Enteroaggregative Escherichia coli: an emerging enteric food borne pathogen. Interdiscip Perspect Infect Dis 2010; 2010:25415910 [CrossRef]
    [Google Scholar]
  2. Croxen MA, Law RJ, Scholz R, Keeney KM, Wlodarska M et al. Recent advances in understanding enteric pathogenic Escherichia coli . Clin Microbiol Rev 2013; 26:822–880 [CrossRef]
    [Google Scholar]
  3. Nataro JP, Mai V, Johnson J, Blackwelder WC, Heimer R et al. Diarrheagenic Escherichia coli infection in Baltimore, Maryland, and new Haven, Connecticut. Clin Infect Dis 2006; 43:402–407 [CrossRef]
    [Google Scholar]
  4. Infante RM, Ericsson CD, Jiang Z-D, Ke S, Steffen R et al. Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. Clin Gastroenterol Hepatol 2004; 2:135–138 [CrossRef]
    [Google Scholar]
  5. Opintan JA, Nataro JP, Gepi-Attee R, Newman MJ, Guerrant RL et al. Pediatric diarrhea in southern Ghana: etiology and association with intestinal inflammation and malnutrition. Am J Trop Med Hyg 2010; 83:936–943 [CrossRef]
    [Google Scholar]
  6. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage 2011; 1:66–85 [CrossRef]
    [Google Scholar]
  7. Dublanchet A, Bourne S. The EPIC of phage therapy. Can J Infect Dis Med Microbiol 2007; 18:15–18 [CrossRef]
    [Google Scholar]
  8. Neguţ AC, Săndulescu O, Popa M, Streinu-Cercel A, Alavidze Z et al. Experimental approach for bacteriophage susceptibility testing of planktonic and sessile bacterial populations - Study protocol. Germs 2014; 4:92–96 [CrossRef]
    [Google Scholar]
  9. Negut AC, Chifiriuc MC, Sandulescu O. Bacteriophage-driven inhibition of biofilm formation in Staphylococcus strains from patients attending a Romanian reference center for infectious diseases. FEMS microbiology 2016
    [Google Scholar]
  10. Negut AC S-C. Bacteriophages–novel biotechnology tools available in clinical practice in Romania. Romanian 2017
    [Google Scholar]
  11. Rose T, Verbeken G, Vos DD, Merabishvili M, Vaneechoutte M et al. Experimental phage therapy of burn wound infection: difficult first steps. Int J Burns Trauma 2014; 4:66–73
    [Google Scholar]
  12. Wright A, Hawkins CH, Anggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 2009; 34:349–357 [CrossRef]
    [Google Scholar]
  13. Furfaro LL, Payne MS, Chang BJ. Bacteriophage therapy: clinical trials and regulatory hurdles. Front Cell Infect Microbiol 2018; 8:376 [CrossRef]
    [Google Scholar]
  14. McCallin S, Sacher JC, Zheng J, Chan DK. Current state of compassionate phage therapy. Viruses 2019; 11:343 [CrossRef]
    [Google Scholar]
  15. Keeney KM, Yurist-Doutsch S, Arrieta M-C, Finlay BB. Effects of antibiotics on human microbiota and subsequent disease. Annu Rev Microbiol 2014; 68:217–235 [CrossRef]
    [Google Scholar]
  16. Vangay P, Ward T, Gerber JS, Knights D. Antibiotics, pediatric dysbiosis, and disease. Cell Host Microbe 2015; 17:553–564 [CrossRef]
    [Google Scholar]
  17. Antonopoulos DA, Huse SM, Morrison HG, Schmidt TM, Sogin ML et al. Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation. Infect Immun 2009; 77:2367–2375 [CrossRef]
    [Google Scholar]
  18. McCallin S, Alam Sarker S, Barretto C, Sultana S, Berger B et al. Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects. Virology 2013; 443:187–196 [CrossRef]
    [Google Scholar]
  19. Sarker SA, McCallin S, Barretto C, Berger B, Pittet A-C et al. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology 2012; 434:222–232 [CrossRef]
    [Google Scholar]
  20. Merabishvili M, Pirnay J-P, Verbeken G, Chanishvili N, Tediashvili M et al. Quality-Controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 2009; 4:e4944 [CrossRef]
    [Google Scholar]
  21. Yu P, Mathieu J, Li M, Dai Z, Alvarez PJJ. Isolation of polyvalent bacteriophages by sequential Multiple-Host approaches. Appl Environ Microbiol 2016; 82:808–815 [CrossRef]
    [Google Scholar]
  22. Legendre P, Minchin PR, O’hara RB. Package ‘vegan. Community ecology; 2013
  23. Blankenberg D, Von Kuster G, Coraor N, Ananda G, Lazarus R et al. Galaxy: a web-based genome analysis tool for experimentalists. Curr Protoc Mol Biol 2010; Unit 19.10:1–21
    [Google Scholar]
  24. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for illumina sequence data. Bioinformatics 2014; 30:2114–2120 [CrossRef]
    [Google Scholar]
  25. Gurevich A, Saveliev V, Vyahhi N, Tesler G. QUAST: quality assessment tool for genome assemblies. Bioinformatics 2013; 29:1072–1075 [CrossRef]
    [Google Scholar]
  26. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 2012; 19:455–477 [CrossRef]
    [Google Scholar]
  27. Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics 2014; 30:2068–2069 [CrossRef]
    [Google Scholar]
  28. Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z et al. Gapped blast and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997; 25:3389–3402 [CrossRef]
    [Google Scholar]
  29. Altschul SF, Wootton JC, Gertz EM, Agarwala R, Morgulis A et al. Protein database searches using compositionally adjusted substitution matrices. FEBS J 2005; 272:5101–5109 [CrossRef]
    [Google Scholar]
  30. Manohar P, Tamhankar AJ, Lundborg CS, Ramesh N. Isolation, characterization and in vivo efficacy of Escherichia phage myPSH1131. PLoS One 2018; 13:e0206278 [CrossRef]
    [Google Scholar]
  31. Forti F, Roach DR, Cafora M, Pasini ME, Horner DS et al. Design of a broad-range bacteriophage cocktail that reduces Pseudomonas aeruginosa biofilms and treats acute infections in two animal models. Antimicrob Agents Chemother 2018; 62: [CrossRef]
    [Google Scholar]
  32. Savkovic SD, Villanueva J, Turner JR, Matkowskyj KA, Hecht G. Mouse model of enteropathogenic Escherichia coli infection. Infect Immun 2005; 73:11611170 [CrossRef]
    [Google Scholar]
  33. Harrington SM, Sheikh J, Henderson IR. The PIC protease of enteroaggregative Escherichia coli promotes intestinal colonization and growth in the presence of mucin. infection and; 2009
  34. Park M, Lee J-H, Shin H, Kim M, Choi J et al. Characterization and comparative genomic analysis of a novel bacteriophage, SFP10, simultaneously inhibiting both Salmonella enterica and Escherichia coli O157:H7. Appl Environ Microbiol 2012; 78:58–69 [CrossRef]
    [Google Scholar]
  35. Galtier M, Sordi LD, Maura D. Bacteriophages to reduce gut carriage of antibiotic resistant uropathogens with low impact on microbiota composition. Environmental 2016
    [Google Scholar]
  36. Caldwell DR, Bryant MP. Medium without rumen fluid for nonselective enumeration and isolation of rumen bacteria. Appl Microbiol 1966; 14:794–801 [CrossRef]
    [Google Scholar]
  37. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA et al. DADA2: high-resolution sample inference from illumina amplicon data. Nat Methods 2016; 13:581–583 [CrossRef]
    [Google Scholar]
  38. Callahan BJ, McMurdie PJ, Holmes SP. Exact sequence variants should replace operational taxonomic units in marker-gene data analysis. ISME J 2017; 11:2639–2643 [CrossRef]
    [Google Scholar]
  39. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T et al. The Silva ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res 2013; 41:D590–D596 [CrossRef]
    [Google Scholar]
  40. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal omega. Mol Syst Biol 2011; 7:539 [CrossRef]
    [Google Scholar]
  41. Price MN, Dehal PS, Arkin AP. FastTree 2 – approximately maximum-likelihood trees for large alignments. PLoS One 2010; 5:e9490 [CrossRef]
    [Google Scholar]
  42. McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One 2013; 8:e61217 [CrossRef]
    [Google Scholar]
  43. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-Seq data with DESeq2. Genome Biol 2014; 15:550 [CrossRef]
    [Google Scholar]
  44. Chao A. Nonparametric estimation of the number of classes in a population. Scandinavian Journal of statistics 1984
    [Google Scholar]
  45. Chao A. Estimating the population size for capture-recapture data with unequal catchability. Biometrics 1987; 43:783–791 [CrossRef]
    [Google Scholar]
  46. Shannon CE. A mathematical theory of communication. Bell System Technical Journal 1948; 27:379–423 [CrossRef]
    [Google Scholar]
  47. Lozupone C, Lladser ME, Knights D, Stombaugh J. UniFrac: an effective distance metric for microbial community comparison. The ISME 2011
    [Google Scholar]
  48. Anderson MJ. Permutational Multivariate Analysis of Variance (PERMANOVA) Wiley StatsRef: Statistics Reference Online; 2014
    [Google Scholar]
  49. Bokete TN, Whittam TS, Wilson RA, Clausen CR, O'Callahan CM et al. Genetic and phenotypic analysis of Escherichia coli with enteropathogenic characteristics isolated from Seattle children. J Infect Dis 1997; 175:1382–1389 [CrossRef]
    [Google Scholar]
  50. Crowther RA. Viruses and the development of quantitative biological electron microscopy. IUBMB Life 2004; 56:239–248 [CrossRef]
    [Google Scholar]
  51. Vandenheuvel D, Lavigne R, Brüssow H. Bacteriophage therapy: advances in formulation strategies and human clinical trials. Annu Rev Virol 2015; 2:599–618 [CrossRef]
    [Google Scholar]
  52. Wilder JN, Lancaster JC, Cahill JL, Rasche ES, Kuty Everett GF. Complete genome sequence of enterotoxigenic Escherichia coli myophage murica. Genome Announc 2015; 3:e01135-15 [CrossRef]
    [Google Scholar]
  53. Cowley LA, Beckett SJ, Chase-Topping M, Perry N, Dallman TJ et al. Analysis of whole genome sequencing for the Escherichia coli O157:H7 typing phages. BMC Genomics 2015; 16:271 [CrossRef]
    [Google Scholar]
  54. Samson JE, Bélanger M, Moineau S. Effect of the abortive infection mechanism and type III toxin/antitoxin system AbiQ on the lytic cycle of Lactococcus lactis phages. J Bacteriol 2013; 195:3947–3956 [CrossRef]
    [Google Scholar]
  55. Aleshkin AV, Rubalskii EO, Volozhantsev NV, Verevkin VV, Svetoch EA et al. A small-scale experiment of using phage-based probiotic dietary supplement for prevention of E. coli traveler's diarrhea. Bacteriophage 2015; 5:e1074329 [CrossRef]
    [Google Scholar]
  56. Cairns BJ, Payne RJH. Bacteriophage therapy and the mutant selection window. Antimicrob Agents Chemother 2008; 52:4344–4350 [CrossRef]
    [Google Scholar]
  57. Chibani-Chennoufi S, Sidoti J, Bruttin A, Dillmann M-L, Kutter E et al. Isolation of Escherichia coli bacteriophages from the stool of pediatric diarrhea patients in Bangladesh. J Bacteriol 2004; 186:8287–8294 [CrossRef]
    [Google Scholar]
  58. Kim M, Kim S, Park B, Ryu S. Core lipopolysaccharide-specific phage SSU5 as an auxiliary component of a phage cocktail for Salmonella biocontrol. Appl. Environ. Microbiol 2014
    [Google Scholar]
  59. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the global enteric multicenter study, GEMs): a prospective, case-control study. The Lancet 2013; 382:209–222 [CrossRef]
    [Google Scholar]
  60. Labrie SJ, Samson JE, Moineau S. Bacteriophage resistance mechanisms. Nat Rev Microbiol 2010; 8:317–327 [CrossRef]
    [Google Scholar]
  61. Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. Future Microbiol 2013; 8:769–783 [CrossRef]
    [Google Scholar]
  62. Jeon J, Park J-H, Yong D. Efficacy of bacteriophage treatment against carbapenem-resistant Acinetobacter baumannii in Galleria mellonella larvae and a mouse model of acute pneumonia. BMC Microbiol 2019; 19:70 [CrossRef]
    [Google Scholar]
  63. Bretin A, Lucas C, Larabi A, Dalmasso G, Billard E et al. AIEC infection triggers modification of gut microbiota composition in genetically predisposed mice, contributing to intestinal inflammation. Sci Rep 2018; 8:12301 [CrossRef]
    [Google Scholar]
  64. Cieplak T, Soffer N, Sulakvelidze A, Nielsen DS. A bacteriophage cocktail targeting Escherichia coli reduces E. coli in simulated gut conditions, while preserving a non-targeted representative commensal normal microbiota. Gut Microbes 2018; 9:391–399 [CrossRef]
    [Google Scholar]
  65. Chattopadhyay MK, Chakraborty R, Grossart H-P, Reddy GS, Jagannadham MV. Antibiotic resistance of bacteria. Biomed Res Int 2015; 2015:5016582 [CrossRef]
    [Google Scholar]
  66. Foster MA, Iqbal J, Zhang C, McHenry R, Cleveland BE et al. Enteropathogenic and enteroaggregative E. coli in stools of children with acute gastroenteritis in Davidson County, Tennessee. Diagn Microbiol Infect Dis 2015; 83:319–324 [CrossRef]
    [Google Scholar]
  67. Ferreira GM, Spira B. The PST operon of enteropathogenic Escherichia coli enhances bacterial adherence to epithelial cells. Microbiology 2008; 154:2025–2036 [CrossRef]
    [Google Scholar]
  68. Casadaban MJ. Transposition and fusion of the lac genes to selected promoters in Escherichia coli using bacteriophage lambda and mu. J Mol Biol 1976; 104:541–555 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001162
Loading
/content/journal/jmm/10.1099/jmm.0.001162
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error